.svg)
.png)
.png)
.svg)
.svg)
A3SMO® based first-in-class medicines and diagnostics for autoimmune and genetic diseases
.webp)
.svg)
.webp)
LDN-051 is a novel faecal biomarker in inflammatory bowel diseases (IBD) and is in development as a non-invasive, in-home, accurate diagnostic toolkit. It provides precise monitoring of disease activity and detection relapses (onset of acute disease flares) and prediction of response to biological therapy in IBD patients.
LDN-051 has shown high specificity and selectivity to active IBD in a Phase IIa clinical study of more than 100 IBD patients. The results also confirmed that LDN-051 levels were not increased in other gastrointestinal diseases, such as diverticulosis, colon polyps or colorectal cancer. The stability of LDN-051 allows the utilization of this biomarker as an in vitro diagnostic tool. This can significantly reduces the healthcare burden by eliminating the need of in-hospital invasive tests (blood tests or endoscopy) and costly imaging modalities.
The patients can perform the test in the comfort of their own home. Regular tests can be carried out and reported remotely by patients to their physicians using a user-friendly cell phone application. Patient follow-ups and prediction of therapeutic responses will be more accurate and flexible. The acute exacerbation of the inflammation can be detected in an early phase preventing severe complications and resultant hospitalizations.
.png)
LDN-071 is being developed as a novel first-in-class, targeted A3SMO®-based oral therapy for patients with IBD. It is a novel approach to utilize local immunosuppression to overcome resistance to biological therapies and to reduce intestinal inflammation.
LDN-071 is a new molecular entity designed and synthetized by our A3SMO® Platform. LDN-071 is resistant to enzymatic digestion and acts locally in the gastrointestinal tract.
.png)
LDN-072 is being explored in different chronic diseases, such as IBD, chronic pancreatitis and liver fibrosis. These indications are currently in pre-clinical phase.
.webp)
LDN-081 is a first-in-class anticancer drug candidate with the potential to transform current cancer treatment strategy. LDN-081 is a new molecular entity designed and synthetized by our A3SMO® Platform and is in development as oral, targeted therapy for different types of gastrointestinal cancer (such as oesophageal, gastric and colorectal cancers).
LDN-081 is resistant to enzymatic digestion and acts locally in the gastrointestinal tract.
.webp)
LDN-025 is being developed as a first-in-class drug candidate to treat Cystic fibrosis for all CFTR genotypes. It is a targeted solution to inhibit ENaC expression. This reduces the harmful overexpression and overactivation of ENaC. Inhibition of ENaC leads to decreased Na+ uptake that decreases fluid reabsorption leading to improved mucus hydration and mucociliary clearance. It overcomes the major current limitation of CF therapies as ENaC inhibition can be an effective therapeutic approach in all CFTR mutations.
.svg)
.png)
.svg)
.svg)
.png)
